SCI Abstract

search
+
Peptides derived from the POU domain of BRN2 show antitumor activity against murine melanoma model cells in vitro and in vivo
Peptides derived from the POU domain of BRN2 show antitumor activity against murine melanoma model cells in vitro and in vivo
The BRN2 transcription factor controls the protein expression involved in cell motility and is overexpressed in melanoma. ...
Trends in renal function following vascular endothelial growth factor inhibitor administration in patients with cancer and diabetes mellitus
Trends in renal function following vascular endothelial growth factor inhibitor administration in patients with cancer and diabetes mellitus
Vascular endothelial growth factor (VEGF) inhibitors are associated with a high incidence of proteinuria. In patients with...
Impact of altitude on hemoglobin dynamics and prognosis in patients with advanced hepatocellular carcinoma receiving antiangiogenic TKIs: A propensity score matched study
Impact of altitude on hemoglobin dynamics and prognosis in patients with advanced hepatocellular carcinoma receiving antiangiogenic TKIs: A propensity score matched study
Antiangiogenic tyrosine kinase inhibitors (TKIs) are associated with elevated hemoglobin [Hb] levels, potentially influenc...
A case report: capillary leak syndrome in a patient receiving high-dose methotrexate, Tislelizumab and zanubrutinib for CNS lymphoma
A case report: capillary leak syndrome in a patient receiving high-dose methotrexate, Tislelizumab and zanubrutinib for CNS lymphoma
The high-dose methotrexate (MTX) regimen is a first-line treatment for primary central nervous system diffuse large B-cell...
Protective effect of celecoxib against capecitabine induced hand and foot syndrome in patients with colorectal Cancer
Protective effect of celecoxib against capecitabine induced hand and foot syndrome in patients with colorectal Cancer
Hand-foot syndrome (HFS) is the most common adverse effect of capecitabine. We aimed at evaluating the protective effect o...
Risk factors and prediction models for cardiotoxicity induced by anthracyclines in malignant chemotherapy
Risk factors and prediction models for cardiotoxicity induced by anthracyclines in malignant chemotherapy
To investigate risk factors for cancer therapy-related cardiac dysfunction (CTRCD) in patients receiving anthracycline-bas...
Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment
Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment
Enasidenib, an isocitrate dehydrogenase-2 (IDH2) inhibitor, is indicated for adult patients with relapsed/refractory acute...
Unrecognized mutations in 2 A wild-type rectal cancer patients receiving postoperative 5-FU-based chemotherapy - do they have a clinical impact?
Unrecognized mutations in 2 A wild-type rectal cancer patients receiving postoperative 5-FU-based chemotherapy - do they have a clinical impact?
The impact of the unrecognized mutational dihydropyrimidine-dehydrogenase-gene-(DPYD)-status on high-grade CTC-AE-grades&#...
DNA-incorporated thioguanine to detect potential non-adherence to maintenance therapy in acute lymphoblastic leukemia
DNA-incorporated thioguanine to detect potential non-adherence to maintenance therapy in acute lymphoblastic leukemia
Adherence to 6-mercaptopurine (6-MP)/methotrexate maintenance treatment for acute lymphoblastic leukemia (ALL) is pivotal ...
Anti-tumor efficacy of RAF/MEK inhibitor VS6766 in KRAS-mutated colorectal cancer cells
Anti-tumor efficacy of RAF/MEK inhibitor VS6766 in KRAS-mutated colorectal cancer cells
Colorectal cancer (CRC) ranks third among most prevalent cancers worldwide. KRAS is the most frequently (30–40%) mut...
Model-informed drug repurposing of proton pump inhibitors for the prevention of oxaliplatin induced peripheral neuropathy: A real-world data analysis and pharmacometrics approach
Model-informed drug repurposing of proton pump inhibitors for the prevention of oxaliplatin induced peripheral neuropathy: A real-world data analysis and pharmacometrics approach
Oxaliplatin (L-OHP) is a platinum-based anticancer agent that induces peripheral neuropathy (OIPN), a dose-limiting toxici...
NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with “quadruple wild-type” (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated
NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with “quadruple wild-type” (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated
Patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) treated with single-agent cetuximab (C) or panitumum...
A thymine-challenge test to prospectively evaluate dihydropyrimidine dehydrogenase activity for risk of severe 5-fluorouracil-induced gastrointestinal toxicity
A thymine-challenge test to prospectively evaluate dihydropyrimidine dehydrogenase activity for risk of severe 5-fluorouracil-induced gastrointestinal toxicity
Inherited dihydropyrimidine dehydrogenase (DPD) deficiency is a risk factor for severe 5-fluorouracil toxicity. We report ...
Biotransformation and disposition of C-labeled sonrotoclax ([C]BGB-11417) in preclinical safety species and characterization of unique contribution from gut microbiome
Biotransformation and disposition of C-labeled sonrotoclax ([C]BGB-11417) in preclinical safety species and characterization of unique contribution from gut microbiome
Sonrotoclax (BGB-11417), a second-generation B-cell lymphoma-2 (BCL-2) inhibitor currently in clinical development, requir...
Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase
Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase
This study aimed to evaluate the relationships between asciminib pharmacokinetics with efficacy in first line (1 ...
A novel cardioprotective mechanism of rosuvastatin: restoring PINK1/parkin-mediated mitophagy via SIRT1/FOXO1 activation in doxorubicin-induced cardiotoxicity
A novel cardioprotective mechanism of rosuvastatin: restoring PINK1/parkin-mediated mitophagy via SIRT1/FOXO1 activation in doxorubicin-induced cardiotoxicity
Chemotherapy remains a key cancer treatment despite advancements in cancer therapy, with doxorubicin (DOX) widely used for...
RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroids
RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroids
The alternative splicing of mRNA precursors allows one gene to yield multiple proteins with distinct functions. CDC-like k...
Anlotinib in cancer therapy: mechanisms of action, clinical applications, and future perspectives
Anlotinib in cancer therapy: mechanisms of action, clinical applications, and future perspectives
This comprehensive review examines anlotinib, a novel multi-target receptor tyrosine kinase inhibitor with potent antitumo...
HER-2 SMASH
HER-2 SMASH
Human epidermal growth factor-2 (HER-2) targeted drugs are used in only HER-2 overexpressed cancers. However, only a small...
Evaluation of urinary vanin-1 for the early prediction of cisplatin-induced acute kidney injury during neoadjuvant chemotherapy for esophageal cancer
Evaluation of urinary vanin-1 for the early prediction of cisplatin-induced acute kidney injury during neoadjuvant chemotherapy for esophageal cancer
Cisplatin (CDDP) induces acute kidney injury (AKI) as a side effect during neoadjuvant chemotherapy (NAC). Urinary vanin-1...
Variations in serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment
Variations in serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment
The blood concentrations of some tyrosine kinase inhibitors are known to decrease with long-term administration. We evalua...
Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy
Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy
To compare the pharmacokinetics and adverse effects of cisplatin administered via intravenous infusion for systemic chemot...
Tenuigenin inhibits osteosarcoma growth via CIP2A/PP2A/NF-κB axis
Tenuigenin inhibits osteosarcoma growth via CIP2A/PP2A/NF-κB axis
Polygala tenuifolia and its active components have been revealed to possess anti-tumor activities. However, the role of Te...
DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancy
DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancy
The enzyme dihydropyrimidine dehydrogenase (DPD) is the primary catabolic pathway of fluoropyrimidines including 5 fluorou...
Nanotechnology and nanobots unleashed: pioneering a new era in gynecological cancer management – a comprehensive review
Nanotechnology and nanobots unleashed: pioneering a new era in gynecological cancer management – a comprehensive review
Gynecological cancers, such as ovarian, cervical, and endometrial malignancies, are notoriously challenging due to their i...
Landscape analysis of adverse events and dose intensity for FDA approved oncology small molecules
Landscape analysis of adverse events and dose intensity for FDA approved oncology small molecules
As development of new oncology small molecule therapies is focused mainly on molecularly targeted agents, the dose selecti...
Pharmacokinetics, mass balance, and metabolism of [14C]PLB1004, a selective and irreversible EGFR-TKI in humans
Pharmacokinetics, mass balance, and metabolism of [14C]PLB1004, a selective and irreversible EGFR-TKI in humans
PLB1004, developed by Beijing Avistone Biotechnology Co., Ltd., is a safe, highly selective, and efficient irreversible ep...
Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study
Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: a cellular study
Based on our previous research, which demonstrated that elevated plasma endoglin (ENG) levels in lung cancer patients were...
Targeting on the PI3K/mTOR: a potential treatment strategy for clear cell ovarian carcinoma
Targeting on the PI3K/mTOR: a potential treatment strategy for clear cell ovarian carcinoma
Ovarian clear cell carcinoma is a highly malignant gynecological tumor characterized by a high rate of chemotherapy resist...
A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome
A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome
Relapsed and/or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome continue to have a poor prognosis...
Load More
format_indent_increase